Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Price:
5.72
CNY
-1.89%
Market Cap:
¥38B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
CN |
Multiples-Based Value
The
Multiples-Based Value for
Shanghai RAAS Blood Products Co Ltd (002252)
under the Base Case is
6.7
CNY.
Compared with the current market price of 5.72 CNY, the stock appears
Undervalued by 15%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Multiples-Based Value
Base Case
6.7
CNY
Undervaluation 15%
Multiples Across Competitors
Competitors Multiples
Shanghai RAAS Blood Products Co Ltd Competitors
Shanghai RAAS Blood Products Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
38B CNY | 5.2 | 24.1 | 25.4 | 25.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
375.5B USD | 6.1 | 89.7 | 14.8 | 20.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.7B USD | 5.2 | 24.8 | 14.4 | 14.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
176.3B USD | 6 | 20.7 | 12.9 | 16 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.5B USD | 9.5 | 28.7 | 21.6 | 22.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.2B USD | 5.7 | 18 | 13.5 | 15.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 11.8 | 37.9 | 40.9 | 41.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.6B AUD | 3 | 32.9 | 11.1 | 13.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
